molecular formula C29H33ClN2O2 B1203769 Loperamide CAS No. 53179-11-6

Loperamide

Cat. No.: B1203769
CAS No.: 53179-11-6
M. Wt: 477 g/mol
InChI Key: RDOIQAHITMMDAJ-UHFFFAOYSA-N
Attention: For research use only. Not for human or veterinary use.
In Stock
  • Click on QUICK INQUIRY to receive a quote from our team of experts.
  • With the quality product at a COMPETITIVE price, you can focus more on your research.

Description

Loperamide is a synthetic phenylpiperidine derivative and μ-opioid receptor agonist primarily used to treat acute and chronic diarrhea. Its chemical structure is analogous to diphenoxylate and haloperidol, but it has been optimized for peripheral action with minimal central nervous system (CNS) penetration due to low oral bioavailability (~0.3%) and P-glycoprotein (P-gp)-mediated efflux . It is metabolized by cytochrome P450 3A4 (CYP3A4) and has a half-life of 10–12 hours, making it longer-acting than diphenoxylate . Common side effects include constipation and abdominal cramps, while severe toxicity is rare unless misused in extremely high doses .

Preparation Methods

Synthetic Routes and Reaction Conditions: The synthesis of loperamide involves multiple steps The resulting compound is then treated with a glacial acetic acid solution of hydrogen bromide to obtain 4-bro-2,2-dibenzylbutyric acidFinally, the compound reacts with 4-hydroxy-4-p-chlorophenylpiperidine to yield this compound .

Industrial Production Methods: Industrial production of this compound typically involves the direct compression or wet granulation processes to prepare tablets. These methods ensure the drug’s stability and bioavailability. Additionally, this compound can be formulated into solid lipid nanoparticles to enhance its oral absorption .

Chemical Reactions Analysis

Metabolism

Loperamide undergoes extensive metabolism, primarily through oxidative N-demethylation, which is mediated by CYP2C8 and CYP3A4, leading to the formation of N-demethyl this compound . CYP2B6 and CYP2D6 have a minor role in this N-demethylation . The metabolites of this compound are pharmacologically inactive . this compound and its metabolites are excreted through biliary excretion, mainly in the feces, with only about 1% of the absorbed dose excreted unchanged in the urine .

Spectrophotometric Determination

This compound hydrochloride (LopH) can be determined through an oxidative-coupling reaction using a phenothiazine reagent in the presence of potassium dichromate .

Principle of Determination

  • The reaction is based on the oxidation of the reagent followed by coupling with LopH to produce a greenish-blue colored complex, which is measured at 625 nm .

Chemical Reactions

  • Oxidation: Phenothiazine undergoes oxidation by acidic potassium dichromate solution to produce the hydroxy-substituted compound .

  • Coupling: The hydroxy-substituted form of phenothiazine is coupled with LopH to form the colored product .

Optimization of Reaction Conditions

ParameterOptimum Value
Phenothiazine reagent2.5 ml of (1x10-3 M)
OxidantPotassium dichromate
Volume of dichromateOptimum volume required to produce optimum absorbance
Time for oxidation stepFive minutes

Conditional Stability Constant

  • The reaction occurs in two drugs to one reagent . The conditional stability constant of the formed blue LopH complex in an aqueous solution is estimated by measuring the absorbances of the reaction mixture containing the same amount of sample and reagent (As) and the absorbances of the reaction mixture containing the same amount of sample and maximum amount of reagent (Am) . The ratio of the dissociation (α= Am-As/As) is found to be 1.795x108 l2.mol-2 .

Cardiac Reactions

This compound can cause serious adverse cardiac reactions, including QT prolongation, Torsades de Pointes, and cardiac arrest, particularly at high doses . Non-clinical data suggests that this compound can inhibit potassium channels (hERG) and cardiac sodium channels at excessive doses, which could result in QT and QRS prolongation and induce arrhythmia . this compound has the potential to slow cardiac conduction through the inhibition of sodium channels and produce conduction arrhythmias at very high concentrations .

Scientific Research Applications

Antidiarrheal Properties

Mechanism of Action : Loperamide works by slowing gut motility, which allows for increased absorption of fluids and electrolytes. It inhibits gastrointestinal secretions induced by various agents, such as prostaglandin E2 and cholera toxin, without significantly affecting cyclic AMP levels in intestinal tissues .

Clinical Efficacy : Numerous studies have demonstrated this compound's efficacy in managing acute and chronic diarrhea. For instance, a systematic review indicated that this compound significantly reduces the duration and severity of diarrhea in children compared to placebo . In a double-blind crossover study involving patients with chronic diarrhea due to ileocolic disease, this compound was found to be superior to placebo in controlling symptoms .

Oncology Applications

Recent research has unveiled this compound's potential role in oncology, particularly concerning leukemia treatment. A study indicated that this compound could induce apoptosis in leukemia cell lines and primary leukemia cells from patients. It was observed to inhibit cell proliferation in a dose-dependent manner and activate apoptotic pathways through mechanisms involving DNA damage . This suggests that this compound may have therapeutic potential beyond its traditional use as an antidiarrheal agent.

Pain Management

This compound has been explored for its analgesic properties, particularly in cases where conventional opioids are contraindicated or lead to adverse effects. A study highlighted the use of this compound in managing pain associated with opioid use disorder, suggesting that it may help alleviate certain symptoms while minimizing the risk of opioid dependency .

Cardiovascular Effects

While this compound is generally safe when used appropriately, there have been reports of serious cardiovascular events associated with its misuse. A case study documented a patient who developed cardiogenic syncope and ventricular tachycardia due to excessive this compound intake. This highlights the importance of monitoring patients who may misuse this medication for non-medical purposes .

Summary Table of this compound Applications

Application AreaDescriptionEvidence Source
AntidiarrhealReduces stool frequency and severity; effective for acute/chronic diarrhea
OncologyInduces apoptosis in leukemia cells; potential therapeutic role
Pain ManagementExplored as an alternative for managing pain linked to opioid use disorder
Cardiovascular EffectsPotentially serious side effects with misuse; documented cases of cardiotoxicity

Mechanism of Action

Loperamide exerts its effects by binding to opioid receptors in the gut wall, specifically the mu-opioid receptors. This binding action inhibits the release of acetylcholine and prostaglandins, which are responsible for increasing gastrointestinal motility. As a result, this compound slows down intestinal contractions, allowing for increased absorption of fluids and electrolytes. This mechanism helps restore normal stool consistency and reduce the frequency of diarrhea .

Comparison with Similar Compounds

Structural Analogs

Diphenoxylate

  • Mechanism: Diphenoxylate, like loperamide, is a phenylpiperidine μ-opioid agonist but is combined with atropine to deter misuse.
  • Efficacy: In a double-blind crossover study, this compound demonstrated superior efficacy in chronic diarrhea management, with fewer CNS side effects (e.g., drowsiness) compared to diphenoxylate .

Haloperidol

  • Structural Similarity : Both this compound and haloperidol are 4-phenylpiperidine derivatives.
  • Key Difference : Haloperidol is a dopamine antagonist used for psychosis, whereas this compound lacks CNS activity. Despite sharing a neurotoxic pyridinium metabolite (LPP+), this compound’s P-gp efflux prevents CNS accumulation, avoiding Parkinsonism-like effects seen with haloperidol .

Mechanism-Based Antidiarrheals

Racecadotril

  • Mechanism : Racecadotril is an enkephalinase inhibitor that reduces intestinal fluid secretion without affecting motility.
  • Efficacy : Clinical trials show comparable efficacy to this compound in acute diarrhea, but racecadotril has a slower onset and lower constipation risk .

Bismuth Subsalicylate

  • Mechanism : Combines antimicrobial and anti-inflammatory actions.
  • Efficacy : Less effective than this compound for rapid symptom relief but useful in infectious diarrhea due to its broad-spectrum antimicrobial activity .
  • Side Effects : Causes tinnitus and blackened stools, which are absent with this compound .

Opioid Analogs with Central Action

Codeine

  • Mechanism : Central μ-opioid agonist with analgesic properties.
  • Efficacy : Similar antidiarrheal efficacy to this compound but with significant sedation and respiratory depression risks .
  • Abuse Potential: High due to euphoric CNS effects, unlike this compound, which is classified as non-narcotic .

Table 1: Comparative Overview of Antidiarrheal Agents

Compound Mechanism Efficacy (vs. This compound) CNS Effects Abuse Potential Key Adverse Effects
This compound Peripheral μ-opioid agonist Reference Minimal Low Constipation, cramps
Diphenoxylate μ-opioid + atropine Less effective Moderate Moderate Drowsiness, dry mouth
Racecadotril Enkephalinase inhibitor Similar None None Headache, nausea
Bismuth subsalicylate Antimicrobial Slower onset None None Tinnitus, dark stools
Codeine Central μ-opioid agonist Similar High High Sedation, respiratory depression

Table 2: Structural and Metabolic Comparisons

Compound Structural Class Bioavailability CYP Metabolism P-gp Substrate Neurotoxic Metabolites
This compound Phenylpiperidine ~0.3% CYP3A4 Yes LPP+ (no toxicity)
Haloperidol Butyrophenone 60–70% CYP3A4/2D6 No Pyridinium (toxic)
Diphenoxylate Phenylpiperidine Moderate CYP3A4 No None reported

Emerging Research and Off-Target Effects

  • siRNA Delivery : this compound enhances endosomal escape of siRNA in vitro, comparable to chloroquine, indicating utility in gene therapy .
  • Peripheral Analgesia: Topical this compound liposomal gel showed antinociceptive effects in arthritis models, though with paradoxical inflammation markers .

Biological Activity

Loperamide is a synthetic opioid primarily used as an antidiarrheal agent. Its biological activities extend beyond gastrointestinal effects, revealing significant implications in immunomodulation and cardiotoxicity. This article explores the diverse biological activities of this compound, supported by case studies, research findings, and data tables.

This compound primarily acts on the μ-opioid receptors in the gut, leading to decreased peristalsis and increased transit time of intestinal contents. This mechanism reduces the frequency of bowel movements and fluid loss. Additionally, this compound has been shown to influence calcium channels, which plays a role in its immunomodulatory effects.

Antimicrobial Activity

Recent studies have highlighted this compound's potential as an antimicrobial agent, particularly against Mycobacterium tuberculosis. Research indicates that this compound enhances the antibacterial response of alveolar macrophages by inducing autophagy and upregulating antimicrobial peptides such as BPI (bactericidal/permeability-increasing protein) and LL37 (cathelicidin) .

Table 1: Summary of this compound's Antimicrobial Effects

EffectMechanismReference
Induction of autophagyEnhances macrophage antibacterial activity
Upregulation of BPIIncreases antimicrobial peptide expression
Reduction of TNFαModulates inflammatory response

Immunomodulatory Effects

This compound's immunomodulatory properties have been observed in various studies. It has been shown to reduce the production of pro-inflammatory cytokines like TNFα while increasing IL-10 levels. This dual effect suggests that this compound may help regulate immune responses during infections, potentially preventing hyperinflammation associated with diseases such as tuberculosis .

Cardiotoxicity and Case Studies

Despite its therapeutic benefits, this compound is associated with significant cardiotoxic effects, particularly when abused. Reports indicate that high doses can lead to life-threatening cardiac arrhythmias and syncope. A notable case involved a 28-year-old male who experienced severe cardiogenic shock after consuming excessive amounts of this compound over several months. He required intensive medical intervention but ultimately showed recovery after appropriate treatment .

Table 2: Overview of Cardiotoxicity Cases Related to this compound Abuse

Patient AgeSymptomsInterventionOutcome
28Cardiac arrest, shockIntralipid emulsion therapyRecovery noted
25Ventricular tachycardiaSupportive careLife-threatening symptoms resolved

Research Findings

A systematic review of cases related to this compound abuse revealed a concerning trend in its misuse. Between 2010 and 2015, there was a reported increase in intentional exposures, with many cases resulting from misuse or suicide attempts. The average dose reported was significantly higher than therapeutic recommendations, highlighting the need for awareness regarding its potential for abuse .

Properties

IUPAC Name

4-[4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl]-N,N-dimethyl-2,2-diphenylbutanamide
Source PubChem
URL https://pubchem.ncbi.nlm.nih.gov
Description Data deposited in or computed by PubChem

InChI

InChI=1S/C29H33ClN2O2/c1-31(2)27(33)29(24-9-5-3-6-10-24,25-11-7-4-8-12-25)19-22-32-20-17-28(34,18-21-32)23-13-15-26(30)16-14-23/h3-16,34H,17-22H2,1-2H3
Source PubChem
URL https://pubchem.ncbi.nlm.nih.gov
Description Data deposited in or computed by PubChem

InChI Key

RDOIQAHITMMDAJ-UHFFFAOYSA-N
Source PubChem
URL https://pubchem.ncbi.nlm.nih.gov
Description Data deposited in or computed by PubChem

Canonical SMILES

CN(C)C(=O)C(CCN1CCC(CC1)(C2=CC=C(C=C2)Cl)O)(C3=CC=CC=C3)C4=CC=CC=C4
Source PubChem
URL https://pubchem.ncbi.nlm.nih.gov
Description Data deposited in or computed by PubChem

Molecular Formula

C29H33ClN2O2
Source PubChem
URL https://pubchem.ncbi.nlm.nih.gov
Description Data deposited in or computed by PubChem

Related CAS

34552-83-5 (mono-hydrochloride)
Record name Loperamide [INN:BAN]
Source ChemIDplus
URL https://pubchem.ncbi.nlm.nih.gov/substance/?source=chemidplus&sourceid=0053179116
Description ChemIDplus is a free, web search system that provides access to the structure and nomenclature authority files used for the identification of chemical substances cited in National Library of Medicine (NLM) databases, including the TOXNET system.

DSSTOX Substance ID

DTXSID6045165
Record name Loperamide
Source EPA DSSTox
URL https://comptox.epa.gov/dashboard/DTXSID6045165
Description DSSTox provides a high quality public chemistry resource for supporting improved predictive toxicology.

Molecular Weight

477.0 g/mol
Source PubChem
URL https://pubchem.ncbi.nlm.nih.gov
Description Data deposited in or computed by PubChem

Physical Description

Solid
Record name Loperamide
Source Human Metabolome Database (HMDB)
URL http://www.hmdb.ca/metabolites/HMDB0004999
Description The Human Metabolome Database (HMDB) is a freely available electronic database containing detailed information about small molecule metabolites found in the human body.
Explanation HMDB is offered to the public as a freely available resource. Use and re-distribution of the data, in whole or in part, for commercial purposes requires explicit permission of the authors and explicit acknowledgment of the source material (HMDB) and the original publication (see the HMDB citing page). We ask that users who download significant portions of the database cite the HMDB paper in any resulting publications.

CAS No.

53179-11-6
Record name Loperamide
Source CAS Common Chemistry
URL https://commonchemistry.cas.org/detail?cas_rn=53179-11-6
Description CAS Common Chemistry is an open community resource for accessing chemical information. Nearly 500,000 chemical substances from CAS REGISTRY cover areas of community interest, including common and frequently regulated chemicals, and those relevant to high school and undergraduate chemistry classes. This chemical information, curated by our expert scientists, is provided in alignment with our mission as a division of the American Chemical Society.
Explanation The data from CAS Common Chemistry is provided under a CC-BY-NC 4.0 license, unless otherwise stated.
Record name Loperamide [INN:BAN]
Source ChemIDplus
URL https://pubchem.ncbi.nlm.nih.gov/substance/?source=chemidplus&sourceid=0053179116
Description ChemIDplus is a free, web search system that provides access to the structure and nomenclature authority files used for the identification of chemical substances cited in National Library of Medicine (NLM) databases, including the TOXNET system.
Record name Loperamide
Source DrugBank
URL https://www.drugbank.ca/drugs/DB00836
Description The DrugBank database is a unique bioinformatics and cheminformatics resource that combines detailed drug (i.e. chemical, pharmacological and pharmaceutical) data with comprehensive drug target (i.e. sequence, structure, and pathway) information.
Explanation Creative Common's Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/legalcode)
Record name Loperamide
Source EPA DSSTox
URL https://comptox.epa.gov/dashboard/DTXSID6045165
Description DSSTox provides a high quality public chemistry resource for supporting improved predictive toxicology.
Record name Loperamide
Source European Chemicals Agency (ECHA)
URL https://echa.europa.eu/substance-information/-/substanceinfo/100.053.088
Description The European Chemicals Agency (ECHA) is an agency of the European Union which is the driving force among regulatory authorities in implementing the EU's groundbreaking chemicals legislation for the benefit of human health and the environment as well as for innovation and competitiveness.
Explanation Use of the information, documents and data from the ECHA website is subject to the terms and conditions of this Legal Notice, and subject to other binding limitations provided for under applicable law, the information, documents and data made available on the ECHA website may be reproduced, distributed and/or used, totally or in part, for non-commercial purposes provided that ECHA is acknowledged as the source: "Source: European Chemicals Agency, http://echa.europa.eu/". Such acknowledgement must be included in each copy of the material. ECHA permits and encourages organisations and individuals to create links to the ECHA website under the following cumulative conditions: Links can only be made to webpages that provide a link to the Legal Notice page.
Record name LOPERAMIDE
Source FDA Global Substance Registration System (GSRS)
URL https://gsrs.ncats.nih.gov/ginas/app/beta/substances/6X9OC3H4II
Description The FDA Global Substance Registration System (GSRS) enables the efficient and accurate exchange of information on what substances are in regulated products. Instead of relying on names, which vary across regulatory domains, countries, and regions, the GSRS knowledge base makes it possible for substances to be defined by standardized, scientific descriptions.
Explanation Unless otherwise noted, the contents of the FDA website (www.fda.gov), both text and graphics, are not copyrighted. They are in the public domain and may be republished, reprinted and otherwise used freely by anyone without the need to obtain permission from FDA. Credit to the U.S. Food and Drug Administration as the source is appreciated but not required.
Record name Loperamide
Source Hazardous Substances Data Bank (HSDB)
URL https://pubchem.ncbi.nlm.nih.gov/source/hsdb/8344
Description The Hazardous Substances Data Bank (HSDB) is a toxicology database that focuses on the toxicology of potentially hazardous chemicals. It provides information on human exposure, industrial hygiene, emergency handling procedures, environmental fate, regulatory requirements, nanomaterials, and related areas. The information in HSDB has been assessed by a Scientific Review Panel.
Record name Loperamide
Source Human Metabolome Database (HMDB)
URL http://www.hmdb.ca/metabolites/HMDB0004999
Description The Human Metabolome Database (HMDB) is a freely available electronic database containing detailed information about small molecule metabolites found in the human body.
Explanation HMDB is offered to the public as a freely available resource. Use and re-distribution of the data, in whole or in part, for commercial purposes requires explicit permission of the authors and explicit acknowledgment of the source material (HMDB) and the original publication (see the HMDB citing page). We ask that users who download significant portions of the database cite the HMDB paper in any resulting publications.

Melting Point

220-228
Record name Loperamide
Source DrugBank
URL https://www.drugbank.ca/drugs/DB00836
Description The DrugBank database is a unique bioinformatics and cheminformatics resource that combines detailed drug (i.e. chemical, pharmacological and pharmaceutical) data with comprehensive drug target (i.e. sequence, structure, and pathway) information.
Explanation Creative Common's Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/legalcode)

Synthesis routes and methods

Procedure details

Octreotide was provided as a sterile lyophilisate and reconstituted with sterile water for injection to yield a stock solution (10 mg/mL). The stock solution was stored refrigerated (2 to 8° C.). On each day of dosing, the stock solution is diluted with sterile water for injection to a final concentration of 0.1 mg/mL. Loperamide hydrochloride was dissolved in saline for injection to yield a final concentration of loperamide base of 0.1 mg/mL (Note: 1 g of loperamide hydrochloride=0.929 g of loperamide base. A correction factor of 1.076 was used for formulation preparation). Loperamide hydrochloride solution is prepared weekly. Compound 552 was formulated as a solution with 10% hydroxypropyl-β-cyclodextrin (97%) in water. In order to verify the concentration of the test articles in the formulations, representative samples (1.0 mL in duplicate, except for octreotide, where only 0.1 mL each will be collected) were collected at appropriate intervals during the study.
Quantity
0 (± 1) mol
Type
reactant
Reaction Step One
Name
Quantity
0 (± 1) mol
Type
solvent
Reaction Step Two
Name
Quantity
0 (± 1) mol
Type
solvent
Reaction Step Three

Retrosynthesis Analysis

AI-Powered Synthesis Planning: Our tool employs the Template_relevance Pistachio, Template_relevance Bkms_metabolic, Template_relevance Pistachio_ringbreaker, Template_relevance Reaxys, Template_relevance Reaxys_biocatalysis model, leveraging a vast database of chemical reactions to predict feasible synthetic routes.

One-Step Synthesis Focus: Specifically designed for one-step synthesis, it provides concise and direct routes for your target compounds, streamlining the synthesis process.

Accurate Predictions: Utilizing the extensive PISTACHIO, BKMS_METABOLIC, PISTACHIO_RINGBREAKER, REAXYS, REAXYS_BIOCATALYSIS database, our tool offers high-accuracy predictions, reflecting the latest in chemical research and data.

Strategy Settings

Precursor scoring Relevance Heuristic
Min. plausibility 0.01
Model Template_relevance
Template Set Pistachio/Bkms_metabolic/Pistachio_ringbreaker/Reaxys/Reaxys_biocatalysis
Top-N result to add to graph 6

Feasible Synthetic Routes

Reactant of Route 1
Reactant of Route 1
Loperamide
Reactant of Route 2
Reactant of Route 2
Loperamide
Reactant of Route 3
Reactant of Route 3
Loperamide
Reactant of Route 4
Reactant of Route 4
Loperamide
Reactant of Route 5
Reactant of Route 5
Loperamide
Reactant of Route 6
Reactant of Route 6
Loperamide

Disclaimer and Information on In-Vitro Research Products

Please be aware that all articles and product information presented on BenchChem are intended solely for informational purposes. The products available for purchase on BenchChem are specifically designed for in-vitro studies, which are conducted outside of living organisms. In-vitro studies, derived from the Latin term "in glass," involve experiments performed in controlled laboratory settings using cells or tissues. It is important to note that these products are not categorized as medicines or drugs, and they have not received approval from the FDA for the prevention, treatment, or cure of any medical condition, ailment, or disease. We must emphasize that any form of bodily introduction of these products into humans or animals is strictly prohibited by law. It is essential to adhere to these guidelines to ensure compliance with legal and ethical standards in research and experimentation.